59 results on '"Hural, John"'
Search Results
2. Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features
3. Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
4. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
5. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
6. Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
7. Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
8. Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19
9. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
10. Achieving intracellular cytokine staining assay concordance on two continents to assess HIV vaccine-induced T-cell responses
11. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
12. Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
13. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim Analysis
14. Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent Vaccines
15. Development of flow cytometry‐based assays to assess the ability of antibodies to bind to SARS‐CoV ‐2‐infected and Spike‐transfected cells and mediate NK cell degranulation
16. Lower SARS-CoV-2-Specific Humoral Immunity in People Living With HIV-1 Recovered From Symptomatic Non-Hospitalized COVID-19
17. Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition
18. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
19. Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
20. Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
21. Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge
22. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults
23. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
24. Infusion Reactions in Persons Receiving the Broadly Neutralizing Antibody VRC01 or Placebo for Reduction of HIV-1 Acquisition: Results From the Phase 2b Antibody Mediated Prevention (AMP) Randomized Trials
25. Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees
26. Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
27. A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults
28. Antigenic competition in CD4 + T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial
29. 1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals
30. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa
31. Daily Vaginal Swabs and Mobile Phone Sex Report for Assessing HIV Virion Exposure Prospectively Among a Cohort of Young Sexually Active Women in South Africa (HVTN 915)
32. Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial
33. Functions of IL-4 and Control of Its Expression
34. Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials
35. The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection
36. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083
37. HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders
38. HIV vaccine-induced sero-reactivity: A challenge for trial participants, researchers, and physicians
39. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
40. Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants
41. Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal
42. Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles
43. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
44. Correction: Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
45. Preexisting Adenovirus Seropositivity Is Not Associated With Increased HIV-1 Acquisition in Three HIV-1 Vaccine Efficacy Trials
46. Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
47. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations
48. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial
49. Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories
50. Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.